226 related articles for article (PubMed ID: 37701438)
1. Platelet status in cancer cachexia progression in Apc
Cunningham P; Unger CA; Patton EA; Aiken A; Browne A; James E; Aladhami AK; Hope Rd MC; VanderVeen BN; Cardaci TD; Murphy EA; Enos RT; Velázquez KT
Front Immunol; 2023; 14():1253587. PubMed ID: 37701438
[TBL] [Abstract][Full Text] [Related]
2. Activity level, apoptosis, and development of cachexia in Apc(Min/+) mice.
Baltgalvis KA; Berger FG; Peña MM; Mark Davis J; White JP; Carson JA
J Appl Physiol (1985); 2010 Oct; 109(4):1155-61. PubMed ID: 20651218
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour-bearing mice.
Brown JL; Rosa-Caldwell ME; Lee DE; Blackwell TA; Brown LA; Perry RA; Haynie WS; Hardee JP; Carson JA; Wiggs MP; Washington TA; Greene NP
J Cachexia Sarcopenia Muscle; 2017 Dec; 8(6):926-938. PubMed ID: 28845591
[TBL] [Abstract][Full Text] [Related]
4. Muscle oxidative capacity during IL-6-dependent cancer cachexia.
White JP; Baltgalvis KA; Puppa MJ; Sato S; Baynes JW; Carson JA
Am J Physiol Regul Integr Comp Physiol; 2011 Feb; 300(2):R201-11. PubMed ID: 21148472
[TBL] [Abstract][Full Text] [Related]
5. Sex differences in the relationship of IL-6 signaling to cancer cachexia progression.
Hetzler KL; Hardee JP; Puppa MJ; Narsale AA; Sato S; Davis JM; Carson JA
Biochim Biophys Acta; 2015 May; 1852(5):816-25. PubMed ID: 25555992
[TBL] [Abstract][Full Text] [Related]
6. Hypothalamic-pituitary-adrenal axis activation and glucocorticoid-responsive gene expression in skeletal muscle and liver of Apc mice.
Martin A; Castells J; Allibert V; Emerit A; Zolotoff C; Cardot-Ruffino V; Gallot YS; Vernus B; Chauvet V; Bartholin L; Schaeffer L; Durieux AC; Hourdé C; Favier FB; Mazelin L; Freyssenet D
J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1686-1703. PubMed ID: 35277933
[TBL] [Abstract][Full Text] [Related]
7. Cachectic skeletal muscle response to a novel bout of low-frequency stimulation.
Puppa MJ; Murphy EA; Fayad R; Hand GA; Carson JA
J Appl Physiol (1985); 2014 Apr; 116(8):1078-87. PubMed ID: 24610533
[TBL] [Abstract][Full Text] [Related]
8. High levels of modified ceramides are a defining feature of murine and human cancer cachexia.
Morigny P; Zuber J; Haid M; Kaltenecker D; Riols F; Lima JDC; Simoes E; Otoch JP; Schmidt SF; Herzig S; Adamski J; Seelaender M; Berriel Diaz M; Rohm M
J Cachexia Sarcopenia Muscle; 2020 Dec; 11(6):1459-1475. PubMed ID: 33090732
[TBL] [Abstract][Full Text] [Related]
9. Skeletal muscle is enriched in hematopoietic stem cells and not inflammatory cells in cachectic mice.
Berardi E; Aulino P; Murfuni I; Toschi A; Padula F; Scicchitano BM; Coletti D; Adamo S
Neurol Res; 2008 Mar; 30(2):160-9. PubMed ID: 18397608
[TBL] [Abstract][Full Text] [Related]
10. Administration of adiponectin receptor agonist AdipoRon relieves cancer cachexia by mitigating inflammation in tumour-bearing mice.
Massart IS; Kouakou AN; Pelet N; Lause P; Schakman O; Loumaye A; Abou-Samra M; Deldicque L; Bindels LB; Brichard SM; Thissen JP
J Cachexia Sarcopenia Muscle; 2024 Apr; ():. PubMed ID: 38572511
[TBL] [Abstract][Full Text] [Related]
11. Skeletal muscle function during the progression of cancer cachexia in the male Apc
VanderVeen BN; Hardee JP; Fix DK; Carson JA
J Appl Physiol (1985); 2018 Mar; 124(3):684-695. PubMed ID: 29122966
[TBL] [Abstract][Full Text] [Related]
12. Quercetin supplementation attenuates the progression of cancer cachexia in ApcMin/+ mice.
Velázquez KT; Enos RT; Narsale AA; Puppa MJ; Davis JM; Murphy EA; Carson JA
J Nutr; 2014 Jun; 144(6):868-75. PubMed ID: 24759931
[TBL] [Abstract][Full Text] [Related]
13. Comparative molecular analysis of early and late cancer cachexia-induced muscle wasting in mouse models.
Sun R; Zhang S; Lu X; Hu W; Lou N; Zhao Y; Zhou J; Zhang X; Yang H
Oncol Rep; 2016 Dec; 36(6):3291-3302. PubMed ID: 27748895
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory signalling regulates eccentric contraction-induced protein synthesis in cachectic skeletal muscle.
Hardee JP; Counts BR; Gao S; VanderVeen BN; Fix DK; Koh HJ; Carson JA
J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):369-383. PubMed ID: 29215198
[TBL] [Abstract][Full Text] [Related]
15. Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK.
White JP; Puppa MJ; Gao S; Sato S; Welle SL; Carson JA
Am J Physiol Endocrinol Metab; 2013 May; 304(10):E1042-52. PubMed ID: 23531613
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the male ApcMin/+ mouse as a hypogonadism model related to cancer cachexia.
White JP; Puppa MJ; Narsale A; Carson JA
Biol Open; 2013 Dec; 2(12):1346-53. PubMed ID: 24285707
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 and cachexia in ApcMin/+ mice.
Baltgalvis KA; Berger FG; Pena MM; Davis JM; Muga SJ; Carson JA
Am J Physiol Regul Integr Comp Physiol; 2008 Feb; 294(2):R393-401. PubMed ID: 18056981
[TBL] [Abstract][Full Text] [Related]
18. Amiloride ameliorates muscle wasting in cancer cachexia through inhibiting tumor-derived exosome release.
Zhou L; Zhang T; Shao W; Lu R; Wang L; Liu H; Jiang B; Li S; Zhuo H; Wang S; Li Q; Huang C; Lin D
Skelet Muscle; 2021 Jul; 11(1):17. PubMed ID: 34229732
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
20. Impairment of aryl hydrocarbon receptor signalling promotes hepatic disorders in cancer cachexia.
Dolly A; Pötgens SA; Thibaut MM; Neyrinck AM; de Castro GS; Galbert C; Lefevre C; Wyart E; Gomes SP; Gonçalves DC; Lanthier N; Baldin P; Huot JR; Bonetto A; Seelaender M; Delzenne NM; Sokol H; Bindels LB
J Cachexia Sarcopenia Muscle; 2023 Jun; 14(3):1569-1582. PubMed ID: 37127348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
